July 08, 2020
As per the report titled ‘Global Atopic Dermatitis (AD) Market: Analysis By Therapy (Biologic, Oral, Topical, Photo), End User, Pipeline, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)’, available with Market Study Report LLC, global atopic dermatitis (AD) market was valued at USD 9095.16 million in 2018, and is anticipated to register strong growth through 2024.
Rising prevalence of atopic dermatitis across the globe owing to increasing pollution levels, rapid urbanization, unhealthy lifestyle, and escalating number of allergies in accordance with hygiene hypothesis is driving the industry growth.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2459406/
Notably, atopic dermatitis is the most common form of eczema, for which no permanent cure is found but novel therapies are emerging in the market which provide temporary relief against the itch and discomfort caused by AD.
Based on therapy, global atopic dermatitis market is categorized into biologic, oral, topical, and photo. Topical therapy is gaining popularity owing to its ease of application on skin and high efficacy. Additionally, elaborate pipeline by pharmaceutical companies is anticipated to bolster the market scenario.
Elaborating on end-user spectrum, the market is classified into hospitals, clinics, and research labs, wherein the foremost segment is poised to hold significant market share in the coming years due to increasing patient visits for AD, asthma, allergy and hay fever treatment.
Considering the regional landscape, Asia Pacific is slated to gain significant traction over the forecast duration on account of increasing pervasiveness of AD and rising per capital expenditure in healthcare industry. Also, Europe and North America is slated to contribute substantially to the market growth.
Major companies operating in global atopic dermatitis market are Anaptys Bio, Sanofi, Pfizer, Regeneron, Abbvie, Allergan, Leo Pharma, Aclaris Therapeutics, Lilly, and Dermira among others.